Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

JOHNSON & JOHNSON

(JNJ)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson : Earns a Spot on Fortune's 2021 Change the World List

10/15/2021 | 01:52pm EST

This week Fortune included Johnson & Johnson on its 2021 Change the World list, which spotlights companies across the globe that have leveraged their core business strategies to drive positive social impact.

While the vaccine makers on last year's list were recognized for their unprecedented collaboration on fighting the coronavirus, this year's list highlights those that are helping expand access to COVID-19 vaccines around the world. Johnson & Johnson is honored to be included for its efforts to make available its Janssen COVID-19 vaccine, for which it received Emergency Use Authorization from the U.S. Food and Drug Administration in February.

To compile the prestigious list, Fortune evaluated companies on the impact they've made in addressing one or more of society's problems, the business results of those actions and the level of innovation involved. Also taken into consideration: how essential the company's initiative was to its overall business strategy.


For more than a century, Johnson & Johnson has relied on a core set of values to guide every aspect of the way it does business.

When COVID-19 hit, the company was able to respond to the once-in-a-lifetime global health challenge by harnessing its capabilities, scientific expertise, global partnerships and experience in helping fight pandemics for over a century-and its 130,000-plus employees around the world mobilized with urgency to address the critical needs of families, communities and healthcare providers.

That sort of innovation and a commitment to social responsibility provide the foundation for Our Credo, the company mission statement that compels everyone who works at Johnson & Johnson to put the needs and well-being of people who depend on its products and services first.

This isn't the first time Fortune has recognized Johnson & Johnson. Earlier this month, Jennifer Taubert, the company's Executive Vice President and Worldwide Chairman, Pharmaceuticals, was named to Fortune's 2021 list of the Most Powerful Women in Business for the sixth consecutive year. In June, the company landed the #4 spot on Fortune's Return on Leadership List, a ranking of the top 100 companies on the Fortune 500 list. And early this year, the brand included Johnson & Johnson among the World's Most Admired Companies, placing it at #1 in the Pharmaceutical category worldwide for the eighth consecutive year.

Johnson & Johnson is proud to be recognized again.

Disclaimer

Johnson & Johnson published this content on 15 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 15 October 2021 17:51:05 UTC.


ę Publicnow 2021
All news about JOHNSON & JOHNSON
12/02Protagonist Therapeutics Picks PN-235 for Mid-Stage Trials in Multiple Indications
MT
12/02Covid-19 - Mobile Vaccination Teams Deployed to Weekly Markets, Inland Regions
AQ
12/02Africans Will Get Wider Access to Vaccines in New Distribution Deal
AQ
12/01Johnson & Johnson's Janssen Lands FDA Nod for Multiple Myeloma Treatment
MT
12/01Zymeworks to Get Milestone Payment After Janssen Doses First Patient With Licensed Anti..
MT
12/01Johnson & Johnson announces significant progress towards its climate goals - 100% renew..
AQ
11/30Oklahoma Supreme Court Concludes Opioid Manufacturer J&J Cannot Be Held Liable Under St..
AQ
11/30JOHNSON & JOHNSON : Janssen Seeks Approval of IMBRUVICA«(ibrutinib) in a Fixed-Duration Re..
PU
11/30Pharmaceutical Names to See Increased Volatility into Year End Amid Omicron Updates, Op..
MT
11/30Johnson & Johnson Units, Aspen Pharmacare Sign Term Sheet for Manufacturing of COVID-19..
MT
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2021 94 251 M - -
Net income 2021 22 542 M - -
Net Debt 2021 493 M - -
P/E ratio 2021 19,0x
Yield 2021 2,65%
Capitalization 414 B 414 B -
EV / Sales 2021 4,39x
EV / Sales 2022 4,08x
Nbr of Employees 134 500
Free-Float 84,3%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Last Close Price 157,09 $
Average target price 184,65 $
Spread / Average Target 17,5%
EPS Revisions
Managers and Directors
Alex Gorsky Chairman & Chief Executive Officer
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Paulus Stoffels Chief Scientific Officer
James D. Swanson Global Chief Information Officer & Executive VP
Charles O. Prince Independent Director
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-0.18%413 555
ROCHE HOLDING AG17.62%341 509
PFIZER, INC.44.09%297 706
NOVO NORDISK A/S64.51%243 534
ELI LILLY AND COMPANY47.55%224 726
ABBVIE INC.8.18%206 612